Integra LifeSciences reports Q3 adjusted EPS 41c, consensus 39c
The Fly

Integra LifeSciences reports Q3 adjusted EPS 41c, consensus 39c

Reports Q3 revenue $380.8M, consensus $375.78M. “Our third-quarter results highlight the early progress we are making to identify and remediate the gaps in our quality management system,” said Jan De Witte, president and CEO of Integra LifeSciences (IART). “We are progressing with the implementation of our compliance master plan across our manufacturing and supply chain operations, which will position us to meet robust market demand and more consistently and reliably deliver to customers, patients, and shareholders.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App